… ii study with cetuximab in combination with 5-FU and cisplatin or carboplatin vs. cetuximab in combination with paclitaxel and carboplatin for treatment of patients with …
G Tsakonas, L Specht, CA Kristensen, MHC Moreno… - Cancers, 2020 - mdpi.com
… Patient Eligibility This multicentre randomized controlled phase 2 trial was conducted at 3
University Hospitals in Sweden and 1 in Denmark. Randomized controlled trials registration …
University Hospitals in Sweden and 1 in Denmark. Randomized controlled trials registration …
A multicenter phase II trial of paclitaxel, carboplatin, and cetuximab followed by chemoradiotherapy in patients with unresectable locally advanced squamous cell …
T Enokida, T Ogawa, A Homma, K Okami… - Cancer …, 2020 - Wiley Online Library
… Accordingly, we conducted a phase II study to assess the feasibility—with a primary focus
on compliance with CRT—and efficacy of induction PCE for those with highly aggressive …
on compliance with CRT—and efficacy of induction PCE for those with highly aggressive …
The MITO CERV-2 trial: A randomized phase II study of cetuximab plus carboplatin and paclitaxel, in advanced or recurrent cervical cancer
S Pignata, G Scambia, D Lorusso, U De Giorgi… - Gynecologic …, 2019 - Elsevier
… randomized phase 2 study to measure the activity of the addition of cetuximab to carboplatin
… In conclusion, our trial showed that the addition of cetuximab to carboplatin and paclitaxel …
… In conclusion, our trial showed that the addition of cetuximab to carboplatin and paclitaxel …
Combination treatment with paclitaxel, carboplatin, and cetuximab (PCE) as first-line treatment in patients with recurrent and/or metastatic nasopharyngeal carcinoma
Y Ueda, T Enokida, S Okano, T Fujisawa, K Ito… - Frontiers in …, 2020 - frontiersin.org
… study, while neutropenia of any grade was observed in 71.4%, no febrile neutropenia developed.
Likewise, in a phase 2 study … On the other hand, in a multicenter retrospective study of R…
Likewise, in a phase 2 study … On the other hand, in a multicenter retrospective study of R…
[HTML][HTML] Weekly paclitaxel, carboplatin, cetuximab, and cetuximab, docetaxel, cisplatin, and fluorouracil, followed by local therapy in previously untreated, locally …
… designed a phase II clinical trial with randomization to two cetuximab-… combined local
therapy in patients with LAHNSCC stratified in different risk categories by HPV status and T-stage. …
therapy in patients with LAHNSCC stratified in different risk categories by HPV status and T-stage. …
Evaluation of pharmacokinetics and safety of cetuximab with cisplatin/carboplatin in patients with advanced solid tumor: Result from phase II studies
RP Perez, E Chen, J Thaddeus Beck… - Pharmacology …, 2019 - Wiley Online Library
… These studies were multicenter, open-label phase II trials designed to evaluate … cetuximab
and cisplatin or carboplatin. Here we report results from two phase II pharmacokinetic studies, …
and cisplatin or carboplatin. Here we report results from two phase II pharmacokinetic studies, …
Safety and efficacy of concurrent carboplatin or cetuximab plus radiotherapy for locally advanced head and neck cancer patients ineligible for treatment with cisplatin
S Hamauchi, T Yokota, T Mizumachi… - International journal of …, 2019 - Springer
… RT for LASCCHN patients, survival—specifically, locoregional control at 2 years, disease free
… phase II study comparing weekly CDDP plus RT with Cmab plus RT in LASCCHN patients, …
… phase II study comparing weekly CDDP plus RT with Cmab plus RT in LASCCHN patients, …
[HTML][HTML] First-line treatment with chemotherapy plus cetuximab in Chinese patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck …
Y Guo, Y Luo, Q Zhang, X Huang, Z Li, L Shen… - European Journal of …, 2021 - Elsevier
… In the CHANGE-2 study, patients in the CT plus cetuximab arm with an ECOG PS of 1 (n
= 116) had better median PFS (5.5 versus 4.0 months; HR: 0.4 [95% CI: 0.3–0.6]) than …
= 116) had better median PFS (5.5 versus 4.0 months; HR: 0.4 [95% CI: 0.3–0.6]) than …
… , and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre …
J Guigay, A Aupérin, J Fayette, E Saada-Bouzid… - The Lancet …, 2021 - thelancet.com
… Results from a phase 2 trial of the TPEx chemotherapy regimen (docetaxel–platinum–cetuximab) …
Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line …
Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line …
Cetuximab-based vs carboplatin-based chemoradiotherapy for patients with head and neck cancer
L Sun, D Candelieri-Surette… - … –Head & Neck …, 2022 - jamanetwork.com
… for patients receiving cisplatin and noncisplatin CRT for HNSCC, the analytic focus of this
study was a comparison of survival with carboplatin-based and cetuximab-based CRT. …
study was a comparison of survival with carboplatin-based and cetuximab-based CRT. …